|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.11 USD | +0.81% |
|
-2.95% | +10.41% |
| 09:16am | Bristol Myers: increase in quarterly dividend | CF |
| 12-10 | Agilent Cancer Diagnostic Assay Receives Certification to Comply with New EU Regulations | MT |
| Capitalization | 115B 110B 102B 90.13B 162B 9,742B 180B 1,262B 467B 4,006B 432B 422B 17,520B | P/E ratio 2024 * |
-17.8x | P/E ratio 2025 * | 11x |
|---|---|---|---|---|---|
| Enterprise value | 153B 146B 136B 120B 217B 12,995B 241B 1,684B 623B 5,344B 576B 563B 23,371B | EV / Sales 2024 * |
3.23x | EV / Sales 2025 * | 3.11x |
| Free-Float |
69.3% | Yield 2024 * |
4.22% | Yield 2025 * | 4.37% |
More valuation ratios
* Estimated data
More news
Last Transcript: Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | +0.38% | ||
| 1 week | -2.95% | ||
| Current month | -4.34% | ||
| 1 month | -5.30% | ||
| 3 months | +16.59% | ||
| 6 months | +31.68% | ||
| Current year | +10.41% |
1 week
56.62
59.76
1 month
55.8260.68
Current year
39.3561.08
1 year
39.3561.08
3 years
39.3581.44
5 years
39.3581.44
10 years
39.3581.44
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 31/10/2023 | |
David Elkins
DFI | Director of Finance/CFO | 56 | 19/11/2019 |
| Chief Tech/Sci/R&D Officer | - | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chairman | 53 | 31/03/2024 | |
Peter Arduini
BRD | Director/Board Member | 59 | 31/03/2016 |
Theodore Samuels
BRD | Director/Board Member | 69 | 20/02/2017 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 380 M€ | +9.09% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 20 M€ | +16.68% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -2.53% | -2.95% | +10.88% | +0.51% | 115B | ||
| -0.44% | -4.07% | +36.30% | +226.05% | 717B | ||
| -0.96% | +1.85% | +18.80% | +106.09% | 492B | ||
| -1.74% | -2.55% | -5.43% | -11.39% | 353B | ||
| -0.74% | -1.18% | +15.29% | +38.97% | 308B | ||
| -1.24% | -1.60% | -4.43% | +37.36% | 252B | ||
| -0.80% | -0.74% | +0.28% | -32.21% | 232B | ||
| -0.60% | -1.14% | +3.20% | +27.27% | 208B | ||
| -0.19% | -2.87% | +2.16% | +17.78% | 199B | ||
| -0.85% | -1.74% | +0.47% | +29.65% | 147B | ||
| Average | -0.18% | -1.10% | +7.75% | +44.01% | 302.35B | |
| Weighted average by Cap. | -0.25% | -1.44% | +13.04% | +78.64% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 47.47B 45.27B 41.98B 37.24B 67.12B 4,025B 74.56B 521B 193B 1,655B 178B 174B 7,238B | 46.89B 44.72B 41.46B 36.78B 66.3B 3,976B 73.65B 515B 191B 1,635B 176B 172B 7,150B |
| Net income | -6.6B -6.29B -5.84B -5.18B -9.33B -560B -10.37B -72.5B -26.85B -230B -24.79B -24.24B -1,006B | 9.69B 9.24B 8.57B 7.6B 13.7B 821B 15.22B 106B 39.41B 338B 36.39B 35.59B 1,477B |
| Net Debt | 38.37B 36.6B 33.93B 30.1B 54.26B 3,254B 60.27B 422B 156B 1,338B 144B 141B 5,851B | 30.87B 29.44B 27.3B 24.21B 43.65B 2,617B 48.49B 339B 126B 1,076B 116B 113B 4,707B |
More financial data
* Estimated data
Employees
34,100
Sector
Pharmaceuticals
Calendar
06/02/2025
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/12/24 | 56.65 $ | -2.53% | 10,578,717 |
| 10/12/24 | 58.12 $ | -1.00% | 6,896,738 |
| 09/12/24 | 58.71 $ | -1.13% | 8,653,505 |
| 06/12/24 | 59.38 $ | +0.92% | 7,277,099 |
| 05/12/24 | 58.84 $ | +0.81% | 8,116,454 |
Delayed Quote Nyse, December 11, 2024 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
56.65USD
Average target price
60.58USD
Spread / Average Target
+6.93%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMY Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition